Systemic cancer treatment linked to 5% skeletal muscle loss over 90 days
Cancer treatment linked to muscle loss in large analysis
A systematic review and meta-analysis of 78 studies (n=10,502) found that systemic cancer treatment is associated with a small but significa…
Chemotherapy and immunotherapy may cause muscle loss in cancer patients, a new analysis of 78 studies finds.
Case report details multimodal treatment for aggressive thyroid carcinoma
First new treatment combination in six months stabilizes advanced thyroid cancer
A 61-year-old man with papillary thyroid carcinoma achieved disease stabilization after thyroidectomy, radiotherapy, and targeted therapy. T…
A 61-year-old man with advanced thyroid cancer saw his disease stop growing after a specific mix of treatments within six months of his diag…
Meta-analysis links emotional distress to worse outcomes in advanced lung cancer
Emotional distress linked to worse lung cancer survival
This systematic review and meta-analysis of 911 patients with advanced NSCLC found emotional distress was significantly associated with redu…
For people with advanced lung cancer, feeling emotionally distressed is tied to lower survival and worse treatment response, a new analysis …
Network meta-analysis compares therapies for liver metastatic uveal melanoma
Liver-directed therapy combined with ICIs leads for metastatic uveal melanoma survival
This systematic review and network meta-analysis synthesized evidence on therapeutic modalities for patients with liver metastatic uveal mel…
A network meta-analysis of 2,585 patients found liver-directed therapy combined with immune checkpoint inhibitors offered the best survival …
Modified Banxia Xiexin Decoction plus chemotherapy shows favorable trends in advanced colorectal cancer
Modified herbal decoction may extend survival time for advanced colorectal cancer patients
This randomized controlled trial in 129 patients with advanced colorectal cancer evaluated modified Banxia Xiexin Decoction (mBXD) granules …
Adding a modified herbal decoction to standard cancer treatment might extend survival time and reduce tumor growth in patients with advanced…
Receptor discordance in metastatic breast cancer lesions associated with poorer overall survival in a retrospective cohort study
When breast cancer changes its targets, does the current treatment still work?
This single-center retrospective cohort study analyzed 436 paired lesion samples from patients with primary and metastatic breast cancer.
Breast cancer often changes its targets, and when tumors lose the proteins doctors rely on, survival drops from 95 to 70 months depending on…